

Press Release

Daiichi Sankyo Enters into Licensing Agreement with Esperion to Market Hypercholesterolemia Treatment in Asia and South America

Tokyo, Japan - (April 27, 2021) –Daiichi Sankyo Company, Limited (hereinafter, Daiichi Sankyo) today announced that it has entered into an exclusive licensing agreement (hereinafter, the Agreement) with Esperion Therapeutics, Inc. (hereinafter, Esperion) to market bempedoic acid, their proprietary oral once-daily drug for the treatment of hypercholesterolemia, in South Korea, Brazil, Taiwan, Hong Kong, Macao, Thailand, Vietnam, Myanmar and Cambodia (hereinafter, the Region).

Under the Agreement, Daiichi Sankyo will be responsible for the commercialization of bempedoic acid and the bempedoic acid/ezetimibe combination, while Esperion will be responsible for their manufacture. In terms of the development operations required for regional applications, Esperion will undertake operations in South Korea and Taiwan, and Daiichi Sankyo will undertake operations in the other territories.

In addition, Daiichi Sankyo will make an upfront payment of \$30 million to Esperion in addition to future, undisclosed milestone payments and sales royalties.

With a novel mechanism of action, bempedoic acid is a drug that inhibits cholesterol and fatty acid biosynthesis by acting on ATP Citrate Lyase, an enzyme that cleaves citrate in the liver. Bempedoic acid was approved in February 2020 in the U.S. and in April of the same year in Europe Union, and its commercialization has been managed by Esperion in the U.S. and by Daiichi Sankyo Europe GmbH (Munich, Germany), a subsidiary of Daiichi Sankyo, in Europe.

The commercialization of bempedoic acid in the Region can take advantage of Daiichi Sankyo's marketing prowess in the cardiovascular field which was established with the anticoagulant LIXIANA® (edoxaban) and other CV products, thus boosting Daiichi Sankyo's regional value.

By taking responsibility for the development and commercialization of bempedoic acid in the Region, Daiichi Sankyo will offer a new treatment option to patients with hypercholesterolemia who have inadequate response to existing drugs, thereby contributing to medical care in the Region.

About Esperion Therapeutics, Inc.

ESPERION is The Lipid Management Company. Our goal is lipid management for everybody, that's why we work hard to make our medicines easy to get, easy to take and easy to have. We discover, develop and commercialize innovative medicines and combinations to lower cholesterol, especially for patients whose needs aren't being met by the status quo. Our entrepreneurial team of industry leaders is inclusive, passionate and resourceful. We are singularly focused on managing cholesterol so you can improve your health easily. For more information, please visit www.esperion.com and follow us on Twitter at www.twitter.com/EsperionInc.

About Daiichi Sankyo

Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose "to contribute to the enrichment of quality of life around the world." In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an "Innovative Global Healthcare Company Contributing to the Sustainable Development of Society." For more information, please visit www.daiichisankyo.com.

Media Contacts:

Japan:

Masashi Kawase
Daiichi Sankyo Co., Ltd.
kawase.masashi.a2@daiichisankyo.co.jp
+81 3 6225 1126 (office)

Investor Relations Contact:

DaiichiSankyoIR@daiichisankyo.co.jp